Literature DB >> 9063669

Serotyping and susceptibility to macrolides and other antimicrobial drugs of Streptococcus pyogenes isolated from patients with invasive diseases in southern Israel.

I Weiss1, Z Gorodnitzky, Z Korenman, P Yagupsky.   

Abstract

Fifty-seven strains of Streptococcus pyogenes isolated from septic patients and 52 isolates from nonbacteremic patients in southern Israel were investigated for their susceptibility to new macrolides and other antimicrobial drugs. In addition, typing of the isolates by M protein and T antigen was performed. All organisms were susceptible to penicillin and chloramphenicol, 59% to tetracycline, and 7% to trimethoprim-sulfamethoxazole. All isolates but one (99%) were susceptible to clarithromycin, azithromycin, erythromycin, and clindamycin. The MIC90 of clarithromycin, erythromycin, and clindamycin was 0.064, 0.125, and 0.094 microgram/ml, respectively. Overall, 96% of the isolates could be typed by T antigen, but only 43% were M-protein typeable. No predominance of any particular M-protein type was observed. No significant differences between blood isolates and organisms derived from other sources were observed in the antibiotic susceptibility patterns or the distribution of serotypes. It is concluded that invasive Streptococcus pyogenes infections in southern Israel are caused by multiple unrelated strains. The organism remains susceptible to macrolides and clindamycin.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9063669     DOI: 10.1007/bf01575115

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  14 in total

1.  Increase in frequency of serious group A streptococcal infections.

Authors:  B Rudensky; M Isaacson; A Beck; J Greenfield
Journal:  Isr J Med Sci       Date:  1992-10

2.  Epidemiologic analysis of group A streptococcal serotypes associated with severe systemic infections, rheumatic fever, or uncomplicated pharyngitis.

Authors:  D R Johnson; D L Stevens; E L Kaplan
Journal:  J Infect Dis       Date:  1992-08       Impact factor: 5.226

3.  Resistance to erythromycin in group A streptococci.

Authors:  H Seppälä; A Nissinen; H Järvinen; S Huovinen; T Henriksson; E Herva; S E Holm; M Jahkola; M L Katila; T Klaukka
Journal:  N Engl J Med       Date:  1992-01-30       Impact factor: 91.245

4.  Outpatient use of erythromycin: link to increased erythromycin resistance in group A streptococci.

Authors:  H Seppälä; T Klaukka; R Lehtonen; E Nenonen; P Huovinen
Journal:  Clin Infect Dis       Date:  1995-12       Impact factor: 9.079

5.  A comparison of azithromycin and penicillin V for the treatment of streptococcal pharyngitis.

Authors:  T M Hooton
Journal:  Am J Med       Date:  1991-09-12       Impact factor: 4.965

6.  Sensitivity of group A streptococci to antibiotics. Prevalence of resistance to erythromycin in Japan.

Authors:  S Maruyama; H Yoshioka; K Fujita; M Takimoto; Y Satake
Journal:  Am J Dis Child       Date:  1979-11

7.  The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis.

Authors:  D L Stevens; A E Gibbons; R Bergstrom; V Winn
Journal:  J Infect Dis       Date:  1988-07       Impact factor: 5.226

8.  A comparative study of clarithromycin and penicillin VK in the treatment of outpatients with streptococcal pharyngitis.

Authors:  R T Bachand
Journal:  J Antimicrob Chemother       Date:  1991-02       Impact factor: 5.790

9.  Changing epidemiology of group A streptococcal infection in the USA.

Authors:  B Schwartz; R R Facklam; R F Breiman
Journal:  Lancet       Date:  1990-11-10       Impact factor: 79.321

10.  Group A streptococcus bacteremia at the Hadassah Medical Center in Jerusalem.

Authors:  A E Moses; D Mevorach; G Rahav; T Sacks; A Simhon; M Shapiro
Journal:  Clin Infect Dis       Date:  1995-05       Impact factor: 9.079

View more
  1 in total

1.  High rate of tetracycline resistance in Streptococcus pyogenes in Iran: an epidemiological study.

Authors:  A Jasir; A Tanna; A Noorani; A Mirsalehian; A Efstratiou; C Schalen
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.